favezelimab,mk-4830,lenvatinib,belzutifan,quavonlimab,pembrolizumab
eisai,merck
['lenva', 'keymaker-u03b', 'rcc,(-irccs),(-srcc),(-urcc)', 'belzutifan']
ph1/2 keymaker-u03b trial with belzutifan + lenvatinib in clear-cell mrcc after anti-pd1/l1 and anti-vegfr. very promising orr of 50% #asco23 
Medical oncologist at @BPorgbr. Former fellow of GU oncology @DanaFarber @Harvard @MOCbrasil. #GUcancer